HPV-Related Malignancy Clinical Trials

8 recruiting

HPV-Related Malignancy Trials at a Glance

8 actively recruiting trials for hpv-related malignancy are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in New Brunswick, Bethesda, and Commack. Lead sponsors running hpv-related malignancy studies include Christian Hinrichs, Merete Haedersdal, and Memorial Sloan Kettering Cancer Center.

Browse hpv-related malignancy trials by phase

Treatments under study

About HPV-Related Malignancy Clinical Trials

Looking for clinical trials for HPV-Related Malignancy? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new HPV-Related Malignancy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about HPV-Related Malignancy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 2

PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer

Cervical CancerRecurrent Cervical CarcinomaHPV-Related Malignancy+2 more
Precigen, Inc24 enrolled3 locationsNCT06157151
Recruiting
Phase 2

A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)

HPV-Related MalignancyHPV-Related CarcinomaHPV Positive Oropharyngeal Squamous Cell Carcinoma+2 more
Memorial Sloan Kettering Cancer Center30 enrolled8 locationsNCT05307939
Recruiting
Phase 1Phase 2

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

Cervical CancerAnal CancerPenile Cancer+14 more
Christian Hinrichs15 enrolled2 locationsNCT05639972
Recruiting
Phase 2

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

Cervical CancerMetastatic CancerAnal Cancer+18 more
Christian Hinrichs20 enrolled3 locationsNCT05686226
Recruiting

Feasibility of HPV Testing With Mail-delivered Sample Collection Kits

HIV InfectionsHPV-Related MalignancyHPV Infection
University of California, San Francisco135 enrolled1 locationNCT07087145
Recruiting

The Organ Transplant Recipient HPV and Skin Cancer Study

Cervical CancerSkin CancerHPV-Related Malignancy+4 more
Merete Haedersdal1,500 enrolled3 locationsNCT05284877
Recruiting
Phase 1

SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas

Cervical CancerAnal CancerPenile Cancer+5 more
The Affiliated Hospital of Qingdao University18 enrolled1 locationNCT06544720
Recruiting

Prognostic Value of Conization and Negative HPV After Conization in AIS and Early Stage Cervical Cancer

Cervix CancerHPV-Related Malignancy
Rambam Health Care Campus200 enrolled1 locationNCT06196190